Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Merdad Parsey sold 25,590 shares of the firm's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares of the company's stock, valued at $9,113,308.50. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Merdad Parsey also recently made the following trade(s):
- On Tuesday, October 1st, Merdad Parsey sold 2,000 shares of Gilead Sciences stock. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00.
Gilead Sciences Stock Performance
Shares of GILD opened at $97.90 on Friday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. The stock has a market capitalization of $121.88 billion, a P/E ratio of 119.39, a P/E/G ratio of 3.13 and a beta of 0.17. The company's fifty day moving average is $84.58 and its two-hundred day moving average is $74.67. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.32.
Top investors are backing this “unlisted” stock
From Pacaso | Ad
When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying attention.
That’s why top firms like SoftBank and Maveron have already backed their latest venture, a company that’s transforming the $1.3 trillion vacation home market.
Learn more about becoming a shareholder in this real estate disruptor before their share price chang
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. Gilead Sciences's revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.29 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.
Gilead Sciences Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.15%. Gilead Sciences's dividend payout ratio is currently 375.61%.
Hedge Funds Weigh In On Gilead Sciences
Several institutional investors have recently bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. grew its stake in shares of Gilead Sciences by 198.3% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 238 shares during the period. nVerses Capital LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth $25,000. Valued Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 161 shares during the period. Cedar Wealth Management LLC grew its stake in shares of Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 160 shares during the period. Finally, Strategic Investment Solutions Inc. IL acquired a new position in shares of Gilead Sciences during the 2nd quarter worth $33,000. 83.67% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
GILD has been the subject of several analyst reports. Leerink Partners upgraded shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $74.00 to $96.00 in a report on Monday, October 21st. Leerink Partnrs upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Monday, October 21st. Robert W. Baird boosted their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a report on Thursday. BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an "outperform" rating in a research report on Thursday. Finally, Barclays lifted their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Thursday. Eleven analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $90.05.
Check Out Our Latest Stock Report on Gilead Sciences
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
